Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.55 |
| ▸ | HTR1B | P28222 | 4/20 | 0.55 |
| ▸ | HTR1A | P08908 | 9/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | HTR1F | P30939 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Avitriptan SCHEMBL29633456 | 1.00 | HTR1D (0.55) | HTR1DHTR1BHTR1AHTR7SLC6A4 | |
| Avitriptan SCHEMBL4352074 | 0.99 | HTR1D (0.54) | HTR1DHTR1BHTR1AHTR7SLC6A4 | |
| SCHEMBL9045333 | 0.95 | HTR1D (0.49) | HTR1DHTR1BHTR1AHTR7SLC6A4 | |
| SCHEMBL4349219 | 0.91 | HTR1A (0.49) | HTR1AHTR7SLC6A4KCNH2ADRA2A | |
| SCHEMBL6363083 | 0.91 | HTR1A (0.49) | HTR1AHTR7SLC6A4KCNH2ADRA2A | |
| SCHEMBL4346029 | 0.90 | HTR1A (0.48) | HTR1DHTR1BHTR1AHTR7SLC6A4 | |
| SCHEMBL4345058 | 0.89 | HTR1A (0.47) | HTR1AHTR7SLC6A4KCNH2ADRA2A | |
| Avitriptan SCHEMBL18396454 | 0.89 | HTR1A (0.57) | HTR1DHTR1BHTR1AHTR7SLC6A4 | |
| SCHEMBL6362007 | 0.88 | HTR1D (0.51) | HTR1DHTR1BHTR1AHTR7SLC6A4 | |
| Hydrochloric Acid SCHEMBL4349599 | 0.88 | HTR1A (0.48) | HTR1AHTR7SLC6A4KCNH2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4681714-A2 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MapLight Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12472255-B2 | Pharmaceutical compositions comprising meloxicam | AXSOME THERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025003517-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | MABEWO PHYTOPHARM AG (CH) | 2025-01-02 | — | — | WO | claimed |
| EP-4483872-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2025-01-01 | — | — | EP | claimed |
| US-20240383973-A1 | METHODS FOR TREATING CALCITONIN GENE-RELATED PEPTIDE (CGRP) - EXPRESSING CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-11-21 | — | — | US | claimed |
| US-20230391749-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF A DELTA-OPIOID MODULATOR | TREVENA, INC. | 2023-12-07 | — | — | US | claimed |
| EP-3999036-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING A TRIPTAN | BIOPHARMA SYNERGIES S L (ES) | 2023-11-08 | — | — | EP | claimed |
| WO-2003015787-A1 | USE OF BIBN4096 IN COMBINATION WITH OTHER ANTIMIGRAINE DRUGS FOR THE TREATMENT OF MIGRAINE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-02-27 | — | — | WO | claimed |
| EP-1083918-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-0969842-A1 | PHARMACEUTICAL COMPOSITION | R.P. Scherer Limited (GB) | 2000-01-12 | — | — | EP | claimed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| WO-1998042344-A1 | PHARMACEUTICAL COMPOSITION | R. P. SCHERER LIMITED (GB) | 1998-10-01 | — | — | WO | claimed |
| US-5550239-A | REACTING TRIALKYLSILYL N-PENTYLPIPERAZINYLPYRIMIDINE DERIVATIVE WITH 4-AMINO-3-IODO-BENZENESULFONAMIDE COMPOUND IN PALLADIUM CATALYZED HETEROANNULATION STEP, REMOVING TRIALKYLSILYL GROUP WITH MINERAL ACID, BASIFYING | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-27 | — | — | US | claimed |
| EP-0711769-A1 | Improved process for large-scale production of BMS 180048 and analogs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-05-15 | — | — | EP | claimed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | claimed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12472255-B2 | Pharmaceutical compositions comprising meloxicam | CA9, CALCA, MC3R | HTR1D 443/4885HTR1B 904/4885HTR1A 163/4885 |
| US-20230391749-A1 | CRYSTALLINE AND AMORPHOUS FORMS OF A DELTA-OPIOID MODULATOR | OPRD1, OPRM1, OPRK1 | HTR1D 368/4885HTR1B 556/4885HTR1A 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.